L-arginine metabolism in myeloid cells controls T-lymphocyte functions

Trends in Immunology

Volumn 24, Issue 6, 2003, Pages 301-305

  Bronte, Vincenzo ^a   Serafini, Paolo ^a   Mazzoni, Alessandra ^b   Segal, David M ^b   Zanovello, Paola ^a  

^a Dept of Oncol/Surgical Sciences ^*  (Italy)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE; ARGININE; GAMMA INTERFERON; INTERLEUKIN 4; LYMPHOTOXIN; N(G) HYDROXYARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PEROXYNITRITE; TUMOR NECROSIS FACTOR ALPHA; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 2; NOS2A PROTEIN, HUMAN; SUPPRESSOR FACTOR;

APOPTOSIS; AUTOIMMUNITY; BONE MARROW CELL; CELL FUNCTION; CELL PROLIFERATION; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOID ORGAN; NONHUMAN; REVIEW; T LYMPHOCYTE; ANIMAL; CELLULAR IMMUNITY; HUMAN; METABOLISM; PHYSIOLOGY;

ANIMALS; ARGINASE; ARGININE; HUMANS; IMMUNITY, CELLULAR; INTERLEUKIN-2; MYELOID CELLS; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; SUPPRESSOR FACTORS, IMMUNOLOGIC; T-LYMPHOCYTES;

EID: 0038519365     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4906(03)00132-7     Document Type: Review

References (45)

1. Bronte V., et al. Tumor-induced immune dysfunctions caused by myeloid suppressor cells. J. Immunother. 24:2001;431-446.
2. + cells. J. Immunol. 161:1998;5313-5320.
3. + T cell responses by dysregulating antigen-presenting cell maturation. J. Immunol. 162:1999;5728-5737.
4. + T cells. Blood. 96:2000;3838-3846.
5. Kusmartsev S., Gabrilovich D.I. Immature myeloid cells and cancer-associated immune suppression. Cancer Immunol. Immunother. 51:2002;293-298.
6. Steinman R.M., Nussenzweig M.C. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc. Natl. Acad. Sci. U. S. A. 99:2002;351-358.
7. Radoja S., et al. CD8(+) tumor-infiltrating T cells are deficient in perforin-mediated cytolytic activity due to defective microtubule-organizing center mobilization and lytic granule exocytosis. J. Immunol. 167:2001;5042-5051.
8. Wu G., Morris S.M. Jr. Arginine metabolism: nitric oxide and beyond. Biochem. J. 336:1998;1-17.
9. Bogdan C. Nitric oxide and the immune response. Nat. Immunol. 2:2001;907-916.
10. Morris S.M. Jr, et al. Differential regulation of arginases and inducible nitric oxide synthase in murine macrophage cells. Am. J. Physiol. 275:1998;E740-747.
11. Salimuddin A., et al. Regulation of the genes for arginase isoforms and related enzymes in mouse macrophages by lipopolysaccharide. Am. J. Physiol. 277:1999;E110-117.
12. Sonoki T., et al. Coinduction of nitric-oxide synthase and arginase I in cultured rat peritoneal macrophages and rat tissues in vivo by lipopolysaccharide. J. Biol. Chem. 272:1997;3689-3693.
13. Bingisser R.M., et al. Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway. J. Immunol. 160:1998;5729-5734.
14. Koblish H.K., et al. Immune suppression by recombinant interleukin (rIL)-12 involves interferon γ induction of nitric oxide synthase 2 (iNOS) activity: inhibitors of NO generation reveal the extent of rIL-12 vaccine adjuvant effect. J. Exp. Med. 188:1998;1603-1610.
15. Angulo I., et al. Early myeloid cells are high producers of nitric oxide upon CD40 plus IFN-γ stimulation through a mechanism dependent on endogenous TNF-α and IL-1α Eur. J. Immunol. 30:2000;1263-1271.
16. Mazzoni A., et al. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J. Immunol. 168:2002;689-695.
17. Apolloni E., et al. Immortalized myeloid suppressor cells trigger apoptosis in antigen-activated T lymphocytes. J. Immunol. 165:2000;6723-6730.
18. Bronte V., et al. IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice. J. Immunol. 170:2003;270-278.
19. Goni O., et al. Immunosuppression during acute Trypanosoma cruzi infection: involvement of Ly6G (Gr1(+))CD11b(+) immature myeloid suppressor cells. Int. Immunol. 14:2002;1125-1134.
20. Duhe R.J., et al. Nitric oxide and thiol redox regulation of Janus kinase activity. Proc. Natl. Acad. Sci. U. S. A. 95:1998;126-131.
21. Saio M., et al. Tumor-infiltrating macrophages induce apoptosis in activated CD8(+) T cells by a mechanism requiring cell contact and mediated by both the cell-associated form of TNF and nitric oxide. J. Immunol. 167:2001;5583-5593.
22. Vincendeau P., et al. Arginases in parasitic diseases. Trends Parasitol. 19:2003;9-12.
23. Mellor A.L., Munn D.H. Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol. Today. 20:1999;469-473.
24. Fallarino F., et al. Functional expression of indoleamine 2,3-dioxygenase by murine CD8α(+) dendritic cells. Int. Immunol. 14:2002;65-68.
25. Grohmann U., et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat. Immunol. 3:2002;1097-1101.
26. Grohmann U., et al. Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol. 24:2003.
27. Louis C.A., et al. Regulation of arginase isoforms I and II by IL-4 in cultured murine peritoneal macrophages. Am. J. Physiol. 276:1999;R237-242.
28. Kung J.T., et al. Suppression of in vitro cytotoxic response by macrophages due to induced arginase. J. Exp. Med. 146:1977;665-672.
29. Ochoa J.B., et al. Effects of L-arginine on the proliferation of T lymphocyte subpopulations. JPEN J. Parenter. Enteral Nutr. 25:2001;23-29.
30. Rodriguez P.C., et al. Regulation of T cell receptor CD3ζ chain expression by L-arginine. J. Biol. Chem. 277:2002;21123-21129.
31. Kiessling R., et al. Tumor-induced immune dysfunction. Cancer Immunol. Immunother. 48:1999;353-362.
32. Shearer J.D., et al. Differential regulation of macrophage arginine metabolism: a proposed role in wound healing. Am. J. Physiol. 272:1997;E181-190.
33. Suh H., et al. Decreased L-arginine during peritonitis in ESRD patients on peritoneal dialysis. Adv. Perit. Dial. 13:1997;205-209.
34. + T cells correlates with Th1/Th2 phenotype. J. Immunol. 160:1998;5347-5354.
35. Mills C.D., et al. M-1/M-2 macrophages and the Th1/Th2 paradigm. J. Immunol. 164:2000;6166-6173.
36. Colleluori D.M., Ash D.E. Classical and slow-binding inhibitors of human type II arginase. Biochemistry. 40:2001;9356-9362.
37. Mossner J., et al. Concomitant down-regulation of L-arginine transport and nitric oxide (NO) synthesis in rat alveolar macrophages by the polyamine spermine. Pulm. Pharmacol. Ther. 14:2001;297-305.
38. Mantovani A., et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 23:2002;549-555.
39. Gordon S. Alternative activation of macrophages. Nat. Rev. Immunol. 3:2003;23-35.
40. Xia Y., Zweier J.L. Superoxide and peroxynitrite generation from inducible nitric oxide synthase in macrophages. Proc. Natl. Acad. Sci. U. S. A. 94:1997;6954-6958.
41. Xia Y., et al. Inducible nitric-oxide synthase generates superoxide from the reductase domain. J. Biol. Chem. 273:1998;22635-22639.
42. + myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation. J. Immunol. 165:2000;779-785.
43. Brito C., et al. Peroxynitrite inhibits T lymphocyte activation and proliferation by promoting impairment of tyrosine phosphorylation and peroxynitrite-driven apoptotic death. J. Immunol. 162:1999;3356-3366.
44. Aulak K.S., et al. Proteomic method identifies proteins nitrated in vivo during inflammatory challenge. Proc. Natl. Acad. Sci. U. S. A. 98:2001;12056-12061.
45. Vallance P., Leiper J. Blocking NO synthesis: how, where and why? Nat. Rev. Drug Discov. 1:2002;939-950.